62023CO0523_INF
Order of the Vice-President of the Court of 7 December 2023 –Biocom California v Commission and Illumina
(Case C‑523/23 P(I))
(Appeal – Intervention – Competition – Concentrations – Pharmaceutical industry market – Decision declaring a concentration incompatible with the internal market and the functioning of the Agreement on the European Economic Area – Action for annulment – Association of undertakings active in the relevant sector with the purpose of defending the interests of its members – Interest in the result of the case)
1.
Judicial proceedings – Intervention – Admissibility criteria – Interest in the result of the case – Concept – Need for a direct and existing interest – Dispute concerning the lawfulness of a Commission merger decision – Direct and existing interest of an association of undertakings active in the relevant sector
(Statute of the Court of Justice, Art. 40, second para.)
(see paragraphs 38-42, 62-68)
2.
Appeal – Grounds – Inadequate statement of reasons – Reliance by the General Court on implied reasoning – Whether permissible – Conditions
(Art. 256 TFEU; Statute of the Court of Justice, Arts 36 and 53, first para.)
(see paragraphs 48-53)
Operative part
1.
The order of the General Court of the European Union of 19 July 2023, Illumina v Commission (T‑709/22, EU:T:2023:416), is set aside.
2.
Biocom California is granted leave to intervene in Case T‑709/22 in support of the form of order sought by Illumina Inc.
3.
The European Commission shall bear its own costs and pay those incurred by Biocom California relating to the present appeal.
4.
Illumina Inc. shall bear its own costs relating to the present appeal.
5.
The costs relating to Biocom California’s application to intervene are reserved.